PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩600 per share · Prices as of the 2026-10-02 close
Cell Biotech has shown a joint improvement in revenue and operating profit since 2025, driven by expanded overseas exports of its DUOLAC brand and domestic marketing gains.
The company has maintained the No. 1 position in domestic probiotics exports for 13 consecutive years, supplying products to 55 countries.
In Denmark's pharmacy market, the brand reached a 46.6% share to overtake the leading local brand, per data compiled in January 2026.
The 2025 annual operating margin reached 14.9%, a clear recovery from 4.1% in 2023.
The innovative colorectal cancer drug candidate PP-P8 has begun patient dosing in a Phase 1 trial at Seoul National University Hospital, expanding the company's biopharmaceutical ambitions.
The stock trades at a level below its per-share net asset value.
Cell Biotech, founded in 1995, is a probiotics-focused company that manufactures and sells health functional foods under its flagship brand DUOLAC.
The company's core competitive edge is its proprietary Dual Coating technology, which uses protein and polysaccharide layers to protect probiotics and has been shown to increase intestinal survival rates by up to 221 times compared to non-coated products, with patents secured in Korea, the United States, and Europe.
Building on this technology, the company uses strains registered under the US FDA's GRAS safety designation, reinforcing its technical credibility in global markets.
The company currently exports to 55 countries including Denmark, Turkey, Russia, Mexico, Indonesia, and Singapore, and became the first Korean company to establish a local sales subsidiary in Denmark as a base for European expansion.
In Denmark's pharmacy market, according to data compiled by market researcher DLIMI in January 2026, the brand reached a 46.6% share, overtaking the leading local brand, while cumulative exports in Germany have surpassed USD 30 million.
In terms of diversification, beyond microbiome-based health functional foods, the company is pursuing expansion into biopharmaceuticals through development of a colorectal cancer treatment.
In the domestic probiotics market, the company competes with large distribution and manufacturing players such as hy, Chong Kun Dang Health, and Cosmax Bio, while overseas it differentiates itself from local brands and global health supplement companies through quality and technology.
Since 2002, the company has participated annually with a standalone booth at Vitafoods Europe, the largest health functional food exhibition in Europe, building brand recognition over more than two decades.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩11.9B | ₩1.3B | 10.8% |
| 2025Q3 | ₩15.4B | ₩2.2B | 14.4% |
| 2025Q4 | ₩14.6B | ₩3.1B | 20.9% |
| 2026Q1 | ₩14.6B | ₩3.2B | 21.8% |
| 2026Q2 | ₩15.8B | ₩1.6B | 10.4% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩50.5B | ₩6.1B | ₩8.3B | 12.0% | 7.7% | 7.2% |
| 2023 | ₩53.8B | ₩2.2B | ₩6.3B | 4.1% | 5.6% | 5.1% |
| 2024 | ₩49.9B | ₩6.8B | ₩15.1B | 13.6% | 12.2% | 5.0% |
| 2025 | ₩53.1B | ₩7.9B | ₩10.1B | 14.9% | 7.7% | 3.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Cell Biotech's annual revenue rose from KRW 50.5 billion in 2022 to KRW 53.8 billion in 2023, but operating profit fell from KRW 6.0 billion to KRW 2.2 billion, sharply lowering the operating margin from 12.0% to 4.1%.
Profitability then recovered quickly, with 2024 revenue of KRW 49.9 billion and operating profit of KRW 6.8 billion (13.6% margin), followed by 2025 revenue of KRW 53.1 billion and operating profit of KRW 7.9 billion, lifting the margin to 14.9%.
Net income jumped from KRW 6.3 billion in 2023 to KRW 15.1 billion in 2024, before settling at KRW 10.1 billion in 2025, suggesting the 2024 spike partly reflected non-operating factors.
On a quarterly basis, revenue of KRW 11.9 billion, operating profit of KRW 1.3 billion, and net income of KRW 0.2 billion in the second quarter of 2025 rose to revenue of KRW 15.4 billion, operating profit of KRW 2.2 billion, and net income of KRW 3.4 billion in the third quarter, continuing into the fourth quarter with revenue of KRW 14.6 billion, operating profit of KRW 3.1 billion, and net income of KRW 4.4 billion.
This momentum continued into 2026, with first-quarter revenue of KRW 14.6 billion, operating profit of KRW 3.2 billion, and net income of KRW 5.4 billion, followed by second-quarter revenue of KRW 15.8 billion, operating profit of KRW 1.6 billion, and net income of KRW 3.6 billion.
These figures are consistent with preliminary second-quarter 2026 results reported in media, which showed sales increasing by 32.8% and operating profit by 28.0% year-on-year.
Combined net income over the most recent four quarters (Q3 2025 through Q2 2026) reached roughly KRW 16.8 billion, indicating that earnings capacity has been sustained relative to the 2024-2025 annual results.
The company has attributed the improvement to the effect of a domestic brand campaign, DUOLAC Probiotics with Strong Survival Power, and expanded overseas exports.
The global probiotics and health functional food market continues to expand, reflecting trends such as gut health, well-aging, and women's health.
In particular, concerns over muscle loss associated with the spread of GLP-1-based obesity treatments have created new demand for probiotics, further segmenting the market beyond traditional digestive health applications.
The fact that a Korean brand has overtaken local brands in Denmark, the birthplace of probiotics, and made inroads in Germany, Europe's largest health functional food market, is viewed as a notable achievement in the industry.
However, global competition is intensifying, with numerous competitors developing similar coating and delivery technologies, accelerating pursuit from later entrants.
In the domestic market, competition continues with large distribution-network companies such as hy and Chong Kun Dang Health, while Cell Biotech seeks differentiation through its proprietary patented technology and a business structure with a relatively high share of overseas exports.
In terms of industry positioning, the company is a small-to-mid cap specialist by revenue scale, but its 13-consecutive-year track record as the top domestic exporter and its market share gains in advanced markets like Denmark and Germany are interpreted as indicators of technological competitiveness.
The company participated with a standalone booth at Vitafoods Europe 2026, held in Barcelona, Spain in May 2026, unveiling new products including a women's health-focused item as part of a broader portfolio diversification effort.
Its innovative colorectal cancer drug candidate PP-P8 is undergoing a Phase 1 trial at Seoul National University Hospital involving a total of 32 metastatic colorectal cancer patients, following a dose-escalation phase to confirm safety before proceeding to a dose-expansion phase to explore efficacy.
The company is reportedly planning to expand its drug development pipeline into areas such as diabetes and gastric cancer treatments, building on this platform.
In its domestic business, the company has stated that a brand campaign featuring a broadcast personality contributed to sales growth, making the continuation of marketing investment and the durability of its effects a point to watch for future results.
Overseas, building on its achievements in Denmark and Germany, the company has stated its plan to pursue major markets including the United States, China, and Japan alongside expansion into emerging markets.
However, no specific revenue or profit guidance or confirmed capacity expansion plans were identified as of the time of this research.
Cell Biotech's earnings have entered a clear recovery phase since bottoming out in 2023, and profitability metrics reflecting the most recent four quarters show improvement compared to the earlier period of weak performance.
The stock trades at a level below its net asset value, which can be viewed as a segment where the market is applying a discount relative to the company's book value.
Given the rapid pace of earnings recovery, the price-to-earnings multiple needs to be interpreted in a different context than the bands seen during the earlier period of losses or low margins.
The company is confirmed to have maintained cash dividends in recent years, which can be viewed as a factor supporting stable cash generation.
However, given the uncertainties surrounding overseas exports and the drug pipeline, valuation interpretation should be considered alongside the sustainability of business performance.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
DUOLAC achieved a 46.6% share in Denmark's pharmacy market, overtaking local brands, while cumulative exports in Germany surpassed USD 30 million. Achievements in the birthplace of probiotics and Europe's largest health functional food market demonstrate technological strength and brand credibility. These advanced-market results can serve as a reference point for entry into other emerging markets.
Operating margin improved markedly from 4.1% in 2023 to 14.9% in 2025, and double-digit margins continued into the first and second quarters of 2026. Media reports indicated first-half operating profit rose 82.6% year-on-year, reflecting a rapid pace of profit improvement. This margin recovery is interpreted as being driven by improved sales mix and expanded overseas exports.
The innovative colorectal cancer drug candidate PP-P8 has begun patient dosing in a Phase 1 trial at Seoul National University Hospital, expanding the company's business scope from health supplements into biopharmaceuticals.
As Korea's first innovative drug developed by recombining probiotic genes, it carries a degree of technical rarity. If the pipeline expands into areas such as diabetes and gastric cancer, it could become a new growth pillar.
Annual revenue grew only modestly from KRW 50.5 billion in 2022 to KRW 53.1 billion in 2025, and operating margin plunged to 4.1% in 2023. As a small health supplement company, earnings volatility can increase due to external factors such as brand campaigns or currency movements.
It should also be noted that quarterly profit growth rates are being compared against a relatively low base from the prior year.
Numerous competitors are developing similar coating and delivery technologies, accelerating pursuit from later entrants. Given that entry barriers in the probiotics market are not absolute, the company faces the ongoing challenge of defending its brand strength and technological edge. Marketing competition with rivals possessing large domestic distribution networks also continues.
PP-P8 is still in a Phase 1 trial involving a small sample of 32 patients, and commercialization will require multiple additional clinical stages and considerable time.
There have been instances where protocol changes delayed the start of dosing beyond initial expectations, underscoring the inherent uncertainty of drug development. The colorectal cancer treatment market has numerous competing drugs, making differentiation a key challenge.
Given the high proportion of overseas exports, the company's earnings can be affected by currency fluctuations. Weakness in European or emerging market currencies, or rising logistics costs, could pressure profitability.
If export dependence on a specific country increases, regulatory changes or demand slowdown in that country could directly affect results.
PP-P8 experienced a delay in patient dosing beyond initial expectations due to protocol changes following IND approval. If safety or efficacy in the Phase 1 trial falls short of expectations, subsequent development could be discontinued.
Drug development is inherently a low-probability-of-success business, and there is a possibility that invested R&D expenses may not be recovered.
Ongoing development of similar technologies by competitors in the global probiotics market raises the possibility of a narrowing technology gap. The need to sustain marketing investment such as brand campaigns may grow, which could translate into cost burdens.
Market share competition with domestic rivals possessing large distribution networks also remains an ongoing variable.
Check whether preliminary third-quarter 2026 results are disclosed to assess whether the revenue and profit growth momentum seen through the second quarter continues.
Following confirmation of safety in the dose-escalation phase, efficacy exploration results in the dose-expansion phase will be an important variable in gauging the future direction of the drug pipeline.
It is worth checking whether the market share and export gains achieved in Denmark and Germany continue into the second half, and whether progress emerges in new market efforts in the United States, China, and Japan.
Confirmation of the fiscal year 2026 dividend and future business plan agenda at the meeting can provide insight into the company's capital allocation direction.
Cell Biotech has maintained the No. 1 position in domestic probiotics exports for 13 consecutive years through its DUOLAC brand, accumulating concrete market share gains in advanced markets such as Denmark and Germany.
Operating margin, which had weakened in 2023, recovered to 14.9% in 2025, and revenue and profit growth has been confirmed to continue through the first half of 2026.
In addition, the ongoing Phase 1 trial of the colorectal cancer drug candidate PP-P8 illustrates the potential for expansion from a health supplement company into biopharmaceuticals.
However, overall revenue scale remains only moderately growing, and factors such as historical earnings volatility, intensifying global competition, and the early-stage risks of the drug pipeline warrant consideration alongside the positives.
The stock trades at a level below its net asset value, and the sustainability of the profit recovery along with progress in overseas exports and drug development are likely to be key variables for future assessment.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.